Acuity Technologies Ltd is a Cambridge-based AI drug discovery company taking a multi-pronged integrative approach to make a step change to existing strategies. 

We aspire to deliver safe and efficacious new therapeutic targets for major diseases, enabling substantial cost and time savings, potentially saving billions in downstream clinical failures resulting from poor target identification.

Acuity is bringing to the fore the mechanistic insights needed to realise AI's true potential in discovering and validating therapeutic targets. Our platform combines world-leading biology with explainable artificial intelligence: transparent, interpretable models that scientists and regulators can interrogate and trust.

Our biology programme is led by Professor David Rubinsztein FRS, Professor of Molecular Neurogenetics at the University of Cambridge and a globally recognised authority on autophagy and neurodegeneration. Our AI team is led by two pioneers in explainable AI, underpinned by an experienced board and management team with successful exits.

https://www.acuity-technologies.com/

Acuity Technologies Ltd

Org chart

Teams

Offices

Acuity Technologies Ltd

Org chart

Teams

Offices

Related companies